Standard
Spironolactone for the Prevention of Microalbuminuria in High-Risk Type 2 Diabetes : Results from the Multicenter Randomized Double-Blind Controlled Trial PRIORITY. / Lindhardt, Morten; Tofte, Nete; Frimodt-Møller, Marie; Currie, Gemma; Delles, Christian; von der Leyen, Heiko; Mischak, Harald; Rossing, Peter.
I:
Journal of the American Society of Nephrology, Bind 30, Nr. Kidney Week Edition, FR-PO247, 2019.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
Lindhardt, M, Tofte, N, Frimodt-Møller, M, Currie, G, Delles, C, von der Leyen, H, Mischak, H
& Rossing, P 2019, '
Spironolactone for the Prevention of Microalbuminuria in High-Risk Type 2 Diabetes: Results from the Multicenter Randomized Double-Blind Controlled Trial PRIORITY',
Journal of the American Society of Nephrology, bind 30, nr. Kidney Week Edition, FR-PO247. <
https://www.asn-online.org/api/download/?file=/education/kidneyweek/archives/KW19Abstracts.pdf>
APA
Lindhardt, M., Tofte, N., Frimodt-Møller, M., Currie, G., Delles, C., von der Leyen, H., Mischak, H.
, & Rossing, P. (2019).
Spironolactone for the Prevention of Microalbuminuria in High-Risk Type 2 Diabetes: Results from the Multicenter Randomized Double-Blind Controlled Trial PRIORITY.
Journal of the American Society of Nephrology,
30(Kidney Week Edition), [FR-PO247].
https://www.asn-online.org/api/download/?file=/education/kidneyweek/archives/KW19Abstracts.pdfVancouver
Lindhardt M, Tofte N, Frimodt-Møller M, Currie G, Delles C, von der Leyen H o.a. Spironolactone for the Prevention of Microalbuminuria in High-Risk Type 2 Diabetes: Results from the Multicenter Randomized Double-Blind Controlled Trial PRIORITY. Journal of the American Society of Nephrology. 2019;30(Kidney Week Edition). FR-PO247.
Author
Lindhardt, Morten ; Tofte, Nete ; Frimodt-Møller, Marie ; Currie, Gemma ; Delles, Christian ; von der Leyen, Heiko ; Mischak, Harald ; Rossing, Peter. / Spironolactone for the Prevention of Microalbuminuria in High-Risk Type 2 Diabetes : Results from the Multicenter Randomized Double-Blind Controlled Trial PRIORITY. I: Journal of the American Society of Nephrology. 2019 ; Bind 30, Nr. Kidney Week Edition.
Bibtex
@article{4de559f31d2a4b64ba52159d2bf038e3,
title = "Spironolactone for the Prevention of Microalbuminuria in High-Risk Type 2 Diabetes: Results from the Multicenter Randomized Double-Blind Controlled Trial PRIORITY",
author = "Morten Lindhardt and Nete Tofte and Marie Frimodt-M{\o}ller and Gemma Currie and Christian Delles and {von der Leyen}, Heiko and Harald Mischak and Peter Rossing",
year = "2019",
language = "English",
volume = "30",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "The American Society of Nephrology",
number = "Kidney Week Edition",
}
RIS
TY - ABST
T1 - Spironolactone for the Prevention of Microalbuminuria in High-Risk Type 2 Diabetes
T2 - Results from the Multicenter Randomized Double-Blind Controlled Trial PRIORITY
AU - Lindhardt, Morten
AU - Tofte, Nete
AU - Frimodt-Møller, Marie
AU - Currie, Gemma
AU - Delles, Christian
AU - von der Leyen, Heiko
AU - Mischak, Harald
AU - Rossing, Peter
PY - 2019
Y1 - 2019
M3 - Conference abstract in journal
VL - 30
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
SN - 1046-6673
IS - Kidney Week Edition
M1 - FR-PO247
ER -
